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Opinion
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an 
autoimmune astrocytopathy that is associated with serum 
aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) [1]. 
This central nervous system (CNS) inflammatory syndrome has 
specific core clinical characteristics, three common presentations 
include optic neuritis that can be bilateral with more severe visual 
impairment as compared with patients with multiple sclerosis, 
longitudinal extensive transverse myelitis (LETM) typically 
involving three or more vertebral segments, and area postrema 
syndrome characterized by intractable hiccups and intractable 
nausea & vomiting.
The association of NMOSD with other autoimmune entities is 
well recognized. The latest diagnostic criteria by the international 
panel of NMO diagnosis include the coexistence of systemic lupus 
erythematous (SLE) and Sjögren syndrome (SS) in the spectrum 
of this condition [2]. Several mechanisms for the co-association 
of AQP4 and SSA have been proposed such as common genetic 
or environmental factors that could predispose the patient for 
autoimmunity. Moreover, the presence of autoantibodies and other 
inflammatory pathways may contribute to the disruption and loss 
of integrity of the blood brain barrier, which could then facilitate 
the CNS manifestations of NMOSD [3]. The clinical implications of 
the association between AQP4 and SSA are poorly understood and 
have not been investigated in a large cohort. 
Our objective was to determine if anti-Ro (SSA) positivity (+) is 
a predictor of relapses and disability among patients with NMOSD. 
Using an ICD-9/ICD-10 diagnosis for NMOSD, after obtaining 
institutional IRB approval, we conducted a retrospective chart 
review at three different medical centers in New Orleans between 
the period of July of 2018 and July 2010. Data extracted included 
age, gender, race, SSA, AQP4-IgG, expanded disability status scale 
(EDSS), disease modifying therapy (DMT), and time since initial 
presentation for each relapse. We used a repeated events Cox 
proportional-hazard model to determine the predictors of relapse 
risk. Furthermore, we also determined the predictors for time to 
sustained EDSS ≥ 7.
We identified 29 patients with NMOSD, of these we found 11 
with SSA antibody. From our 29 patients with NMOSD, mean age 
was ± SD = 45 ± 13 years, 79% were female. SSA positivity was 
determined by serological testing and patients were included 
regardless of a clinical diagnosis of Sicca syndrome. As far as race, 
72% were African American (AA), and 18% were Caucasian. All of 
our patients met diagnostic criteria for NMOSD2, 69% were AQP4+ 
(cell-based assay). 30% of patients were SSA+ and all of these 
patients were African American (AA) females. 24% patients were 
AQP4+ and SSA+. 
Patients with NMOSD that were positive for SSA+ were at higher 
risk of relapse (HR 1.95(1.10,3.44)), p=0.0017. AQP4+ patients 
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showed a trend for higher relapse risk (HR 1.23(0.65,2.33)), 
p=0.3). After controlling for gender and age, SSA+ remained a 
significant predictor of relapse risk in patients with NMOSD (HR 
1.70(1.10,2.65)), p=0.03). 
Restricting the analysis to women with NMOSD also showed 
that SSA+ was a significant predictor of relapse risk. (HR 
1.79(1.19,2.69)), p=0.03). 
Moreover, there was a trend in SSA patients for higher risk 
of sustained severe disability (EDSS≥7) (HR 5.0(0.9-27), p=0.06. 
Another observation was that the use of Rituximab reduced the 
risk of relapse (HR 0.27 (0.10, 0.77), p=0.003 compared to no DMT. 
Our study is limited due to its retrospective design; however, 
our results suggest that patients with NMOSD and SSA+ have almost 
twice the risk of relapse, and a trend toward greater disability. 
These findings may support the previously proposed mechanism 
of co-association between AQP4 and SSA where the presence of 
several autoantibodies could disrupt the BBB and therefore lead to 
more devastating clinical syndrome3. 
These findings may help guide clinicians when approaching 
patients presenting with NMOSD and SSA positivity. It would be 
reasonable for one to more cautiously monitor these patients and 
consider using more aggressive therapies in this subset of patients 
with NMOSD. These results need to be validated in a larger cohort.
Statistical Analysis
Our statistical analysis was conducted by senior author, Dr. 
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